- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07215234
- Original retssag
En sikkerheds- og effektivitetsundersøgelse af en engangs intravitreal injektion af SAR446597 hos deltagere med geografisk atrofi sekundært til aldersrelateret makuladegeneration
En fase 1/2, undersøgelse for at evaluere sikkerheden, tolerabiliteten og effektiviteten af engangs intravitreal dosis af SAR446597 hos deltagere med geografisk atrofi sekundært til aldersrelateret makuladegeneration
This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
The core phase duration will be approximately 2 years for each participant. An Extended Follow-Up (EFU) phase of 3 years follows the core phase.
The treatment is a one-time intravitreal injection of SAR446597 (or sham as applicable in Part II).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Trial Transparency email recommended (Toll free for US & Canada)
- Telefonnummer: option 6 800-633-1610
- E-mail: contact-us@sanofi.com
Studiesteder
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2000
- Rekruttering
- Investigational Site Number : 0360003
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Rekruttering
- Investigational Site Number : 0360002
-
-
Victoria
-
East Melbourne, Victoria, Australien, 3002
- Rekruttering
- Investigational Site Number : 0360001
-
-
-
-
-
London, Det Forenede Kongerige, W1G 9AX
- Rekruttering
- Investigational Site Number : 8260001
-
-
-
-
Arizona
-
Peoria, Arizona, Forenede Stater, 85381
- Rekruttering
- Associated Retina Consultants - Peoria- Site Number : 8400011
-
Scottsdale, Arizona, Forenede Stater, 85255
- Rekruttering
- Retina Macula Institute of Arizona- Site Number : 8400028
-
-
California
-
Beverly Hills, California, Forenede Stater, 90211
- Rekruttering
- Retina-Vitreous Associates Medical Group - Beverly Hills- Site Number : 8400033
-
Encino, California, Forenede Stater, 91436
- Rekruttering
- The Retina Partners- Site Number : 8400040
-
Oxnard, California, Forenede Stater, 93036
- Rekruttering
- California Retina Consultants - Oxnard - North Ventura Road- Site Number : 8400014
-
Sacramento, California, Forenede Stater, 95825
- Rekruttering
- Retinal Consultants - Sacramento - Parkcenter Drive- Site Number : 8400054
-
Torrance, California, Forenede Stater, 90503
- Rekruttering
- Macula Retina Vitreous Center - Torrance- Site Number : 8400053
-
Walnut Creek, California, Forenede Stater, 94598
- Rekruttering
- Bay Area Retina Associates - Walnut Creek - Lennon Lane- Site Number : 8400039
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32607
- Rekruttering
- Vitreo Retinal Associates - Gainesville- Site Number : 8400004
-
St. Petersburg, Florida, Forenede Stater, 33711
- Rekruttering
- Retina Vitreous Associates of Florida - St. Petersburg- Site Number : 8400002
-
Stuart, Florida, Forenede Stater, 34994
- Rekruttering
- East Florida Eye Institute- Site Number : 8400038
-
-
Georgia
-
Augusta, Georgia, Forenede Stater, 30909
- Rekruttering
- Southeast Retina Center- Site Number : 8400044
-
-
Illinois
-
Lemont, Illinois, Forenede Stater, 60439
- Rekruttering
- University Retina - Lemont- Site Number : 8400005
-
-
Maryland
-
Chevy Chase, Maryland, Forenede Stater, 20815
- Rekruttering
- The Retina Group of Washington - Chevy Chase- Site Number : 8400009
-
Hagerstown, Maryland, Forenede Stater, 21740
- Rekruttering
- Cumberland Valley Retina Consultants - Hagerstown- Site Number : 8400003
-
Towson, Maryland, Forenede Stater, 21204
- Rekruttering
- Retina Specialist- Site Number : 8400055
-
-
Nevada
-
Reno, Nevada, Forenede Stater, 89502
- Rekruttering
- Sierra Eye Associates- Site Number : 8400021
-
-
North Carolina
-
Wake Forest, North Carolina, Forenede Stater, 27587-3803
- Rekruttering
- North Carolina (Nc) Retina Associates - Wake Forest Office- Site Number : 8400059
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Rekruttering
- Oregon Retina- Site Number : 8400017
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forenede Stater, 18017-9412
- Rekruttering
- Mid Atlantic Retina - Bethlehem- Site Number : 8400031
-
Erie, Pennsylvania, Forenede Stater, 16505
- Rekruttering
- Erie Retina Research- Site Number : 8400035
-
-
South Carolina
-
Ladson, South Carolina, Forenede Stater, 29456
- Rekruttering
- Charleston Neuroscience Institute - Ladson- Site Number : 8400016
-
Ladson, South Carolina, Forenede Stater, 29456
- Rekruttering
- Charleston Neuroscience Institute - Ladson- Site Number : 8400046
-
-
Texas
-
Arlington, Texas, Forenede Stater, 76012
- Rekruttering
- Texas Retina Associates - Arlington- Site Number : 8400056
-
Austin, Texas, Forenede Stater, 78750
- Rekruttering
- Austin Clinical Research - Austin - Anderson Mill Road- Site Number : 8400007
-
Austin, Texas, Forenede Stater, 78705
- Rekruttering
- Retina Consultants of Austin- Site Number : 8400015
-
Bellaire, Texas, Forenede Stater, 77401
- Rekruttering
- Retina Consultants of Texas - Bellaire- Site Number : 8400019
-
Dallas, Texas, Forenede Stater, 75231
- Rekruttering
- Retina Foundation of the Southwest- Site Number : 8400001
-
Dallas, Texas, Forenede Stater, 75231
- Rekruttering
- Texas Retina Associates - Dallas- Site Number : 8400006
-
San Antonio, Texas, Forenede Stater, 78240
- Rekruttering
- Retinal Consultants of Texas - San Antonio- Site Number : 8400012
-
Southlake, Texas, Forenede Stater, 76092
- Rekruttering
- Retina Center of Texas (RCT) - Southlake- Site Number : 8400048
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 60 years old or above
- Participants with diagnosis of GA secondary to age-related macular degeneration (AMD)
- Study eye with best corrected visual acuity (BCVA) ETDRS Snellen equivalent for dose escalation (Part I) between 20/40 and 20/320 and for expansion (Part II) equal or better than 20/200
- Study eye with GA lesion measuring between 2.5 and 17.5 mm2 for dose escalation (Part I) and between 2.5 and 14.0 mm2 for expansion (Part II). For multifocal disease, study eye with at least one single lesion of more than 1.25mm2 for both Part I and Part II
Exclusion Criteria:
- GA in the study eye caused by a disease different than AMD
- Presence of neovascularization or a history of treatment with an anti vascular endothelial growth factor agent in the study eye
- Any condition or treatment (ocular or systemic) or medical or surgical history in the study eye that may prevent visual acuity improvement or interfere with ocular safety or efficacy assessments
- Current or history of systemic complement targeting treatment in the past 12 months
- Use of ocular corticosteroids for 4 months (for ocular or periocular injections), 6 months (for intraocular implants) or 3 years (for long lasting intraocular implants) prior to screening in the study eye
- History of macular laser photocoagulation treatment, photodynamic- or thermotherapy or photo biomodulation in the study eye
- History of active ocular infection in the study eye in 6 months prior to screening
- Presence of active ocular or periocular infections
- Active uncontrolled glaucoma in the study eye
- History of uveitis or scleritis in either eye
- Previous gene therapy in either eye
- Any significant poorly controlled illness that would preclude study compliance and follow up
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part I - SAR446597 open-label (OL)
Participants will receive SAR at a dose specified for each cohort. Multiple dose levels of SAR446597 will be evaluated in successive cohorts of participants. |
Intravitreal injection |
|
Eksperimentel: Part II - SAR446597 Dose A
Participants will receive SAR at a dose specified for each arm. |
Intravitreal injection |
|
Eksperimentel: Part II - SAR446597 Dose B
Participants will receive SAR at a dose specified for each arm. |
Intravitreal injection |
|
Sham-komparator: Part II - Sham control
Participants will receive Sham at a dose specified for each arm. |
Sham injection |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Forekomst og sværhedsgrad af okulær og ikke-okulær behandlingsvækkende bivirkning (TEAE'er)
Tidsramme: Dag 1 til uge 104
|
Dag 1 til uge 104
|
|
Forekomst og sværhedsgrad af okulær og ikke-okulær behandling-opstående alvorlige bivirkninger (TESAES)
Tidsramme: Dag 1 til uge 104
|
Dag 1 til uge 104
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring i firkantet rod-transformeret (MM) og utransformeret område (MM2) af GA
Tidsramme: Baseline, uge 52, uge 104
|
Baseline, uge 52, uge 104
|
|
Ændring i bedst korrigerede synsstyrke (BCVA) fra baseline til uge 52 og uge 104 efter SAR446597-administration målt med den tidlige behandling af diabetisk retinopati-undersøgelse (ETDRS) -diagram
Tidsramme: Baseline, uge 52, uge 104
|
Baseline, uge 52, uge 104
|
|
Procentdel af deltagere uden tab af BCVA på ≥15 ETDRS -breve fra baseline i undersøgelsesøjet
Tidsramme: Baseline, uge 52, uge 104
|
Baseline, uge 52, uge 104
|
|
Forekomst og sværhedsgrad af okulære og ikke-okulære tees og tesaes inklusive klinisk signifikante ændringer i sikkerhedsparametre
Tidsramme: Uge 260 eller slutningen af studiet
|
Uge 260 eller slutningen af studiet
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- DFI18231
- 2025-524508-31 (Registry Identifier: CTIS)
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .